Understanding how to protect the heart from cancer treatment side effects
Elucidating Protective Mechanisms for Cardiotoxicity of Kinase Inhibitors
This study is looking at how the cancer drug ibrutinib can affect heart health, and it's trying to find ways to protect your heart while you receive treatment, so you can feel safer during your cancer journey.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10935741 on NIH RePORTER |
What this research studies
This research investigates the cardiovascular toxicities associated with modern cancer treatments, particularly focusing on the drug ibrutinib, which is used for treating B-cell malignancies. The study aims to develop strategies to protect the heart from these toxic effects by using advanced techniques such as high throughput assays and deep learning algorithms to analyze heart cell responses. By examining how ibrutinib affects heart cells derived from human stem cells, researchers hope to identify potential therapeutic targets that can mitigate heart-related side effects. The ultimate goal is to improve the safety of cancer treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing treatment for B-cell malignancies who are at risk of developing heart complications.
Not a fit: Patients who are not receiving kinase inhibitors or those without cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments with fewer heart-related side effects for patients.
How similar studies have performed: Previous research has shown promise in using similar approaches to mitigate drug-induced cardiac toxicities, indicating potential for success in this area.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Mercola, Mark — Stanford University
- Study coordinator: Mercola, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.